Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT ID: NCT07231419

Last Updated: 2026-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

734 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-21

Study Completion Date

2027-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Peripheral Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Suzetrigine (SUZ)

Participants will be randomized to receive SUZ.

Group Type EXPERIMENTAL

Suzetrigine

Intervention Type DRUG

Tablets for oral administration

Placebo

Participants will be randomized to receive placebo matched to SUZ.

Group Type PLACEBO_COMPARATOR

Placebo (matched to SUZ)

Intervention Type DRUG

Placebo matched to SUZ for oral administration.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suzetrigine

Tablets for oral administration

Intervention Type DRUG

Placebo (matched to SUZ)

Placebo matched to SUZ for oral administration.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VX-548 SUZ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body weight greater than or equal to (≥)45 kilogram (kg)
* Body mass index (BMI) ≥18 to less than (\<) 40 kilogram per meter square (kg/m\^2)
* Diagnosis of diabetes mellitus type 1 or type 2 and with glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN for at least 1 year
* Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period

Exclusion Criteria

* More than 3 missing daily NPRS scores during the 7-day Baseline Period
* Received Journavx within 30 days of study drug dosing
* Any sensory abnormality (excluding DPN) as pre-specified in the protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vertex Pharmaceuticals Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Velocity Clinical Research -San Bernardino

San Bernardino, California, United States

Site Status RECRUITING

Velocity Clinical Research - Hallandale Beach

Hallandale, Florida, United States

Site Status RECRUITING

CNS Healthcare - Jacksonville

Jacksonville, Florida, United States

Site Status RECRUITING

Health Awareness, Inc. - Jupiter

Jupiter, Florida, United States

Site Status RECRUITING

3Sync Research -Miami Lakes

Miami Lakes, Florida, United States

Site Status RECRUITING

Accel Research - Decatur

Decatur, Georgia, United States

Site Status RECRUITING

Healthcare Research Network - Flossmoor IL

Tinley Park, Illinois, United States

Site Status RECRUITING

Healthcare Research Network - Hazelwood MO

Hazelwood, Missouri, United States

Site Status RECRUITING

AMR Kansas City

Kansas City, Missouri, United States

Site Status RECRUITING

Velocity Clinical Research - Cleveland

Beachwood, Ohio, United States

Site Status RECRUITING

Velocity Clinical Research - Medford

Medford, Oregon, United States

Site Status RECRUITING

Velocity Clinical Research - Providence

East Greenwich, Rhode Island, United States

Site Status RECRUITING

Zenos Clinical Research

Dallas, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Medical Information

Role: CONTACT

6173416777

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VX24-548-111

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BMS-741672 for Diabetic Neuropathic Pain
NCT00683423 COMPLETED PHASE2